OCHRE BIO
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
OCHRE BIO
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2019-09-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ochre-bio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
9.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Domain Not Resolving
Similar Organizations
Allakos
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
D2G Oncology
D2G Oncology is a biotechnology company that specializes in relating drugs to genotypes to transform precision cancer therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bioverge
Bioverge investment in Series A - Ochre Bio
Milad Alucozai
Milad Alucozai investment in Series A - Ochre Bio
FAST — by GETTYLAB
FAST — by GETTYLAB investment in Series A - Ochre Bio
LifeLink Ventures
LifeLink Ventures investment in Series A - Ochre Bio
Acequia Capital (AceCap)
Acequia Capital (AceCap) investment in Series A - Ochre Bio
Hoxton Ventures
Hoxton Ventures investment in Seed Round - Ochre Bio
Hermes-Epitek
Hermes-Epitek investment in Seed Round - Ochre Bio
Apollo Health Ventures
Apollo Health Ventures investment in Seed Round - Ochre Bio
BACKED VC
BACKED VC investment in Seed Round - Ochre Bio
Khosla Ventures
Khosla Ventures investment in Seed Round - Ochre Bio
Official Site Inspections
http://www.ochre-bio.com Semrush global rank: 6.66 M Semrush visits lastest month: 892
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ochre Bio"
Ochre Bio - Crunchbase Company Profile & Funding
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use …See details»
Ochre Bio 2025 Company Profile: Valuation, Funding & Investors
Ochre Bio was founded in 2019. Where is Ochre Bio headquartered? Ochre Bio is headquartered in Oxford, United Kingdom. What is the size of Ochre Bio? Ochre Bio has 61 total employees. …See details»
Ochre Bio - LinkedIn
Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor ...See details»
Ochre Bio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - Ochre Bio . 2: …See details»
Member profile: Ochre Bio Ltd | BIA
Ochre Bio develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic …See details»
Ochre Bio - VentureRadar
Ochre Bio develops genomic medicines for cardiometabolic disease. Ochre employs spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing …See details»
RNA Therapies in Liver Disease: Insights from Ochre …
Jan 24, 2024 In this interview, we speak with Jack O'Meara, co-founder and CEO of Ochre Bio, a pioneering force in liver disease treatment. O'Meara shares insights into Ochre Bio's innovative RNA therapies ...See details»
Ochre Bio - Craft
Ochre Bio is a biotechnology company that builds a platform to rejuvenate transplant livers. It develops RNA therapies for chronic liver disease using a combination of genomics, machine …See details»
Ochre Bio
"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence." Dr. Chinwe Ukomadu, …See details»
Ochre Bio Company Information - Funding, Investors, and More
Key Insights: Ochre Bio October 2022 Series A Funding Round: $30m Ochre Bio Seed round, June 2021: $9.6m Ochre Bio June 2021 Seed Funding Round: $9.6m Ochre Bio March 2020 …See details»
EIT Health-supported start-up Ochre Bio signs $1BN+ deal with ...
May 7, 2024 Oxford-based Ochre Bio has closed a deal to the value of $1BN+ with European drugmaker Boehringer Ingelheim. Ochre Bio is a biotechnology company developing RNA …See details»
Ochre Bio - Products, Competitors, Financials, Employees, …
Ochre Bio is a biotechnology company that focuses on developing RNA therapies for chronic liver diseases. Use the CB Insights Platform to explore Ochre Bio's full profile. ... Arctoris is a tech …See details»
Ochre Bio - BIO International Convention 2025
Ochre Bio is a biotechnology company developing novel RNA medicines for late-stage chronic liver diseases, including liver fibrosis and cirrhosis. Its proprietary discovery platform combines …See details»
Ochre Bio - Updates, News, Events, Signals & Triggers - Crunchbase
Ochre Bio may be growing as evidenced by a series of partnerships and financial deals that indicate an expansion of their operations and potential revenue streams. The company has …See details»
Oxford biotech raises funds to make RNA treatments for liver …
Oct 10, 2022 Ochre Bio has already analysed data from more than 1,000 diseased livers in collaboration with Oxford university in an approach called deep phenotyping, which combines …See details»
Ochre Bio and Boehringer enter CLD regenerative therapy deal
Apr 23, 2024 This partnership will leverage Ochre Bio’s ability to expedite the discovery and validation of new targets for liver diseases, building on the company’s strengths in human data …See details»
Ochre Bio Secures $1B in Funding for Breakthrough RNA …
Dec 23, 2024 Ochre Bio, a pioneering biotechnology company at the forefront of developing innovative RNA therapies for chronic liver diseases, has successfully raised $1 billion in its …See details»
Ochre Bio | Sifted: AI-Powered Company Profiles & Insights
Ochre Bio. Oxford, United Kingdom. Founded in 2019. Website. Overview Overview. Precision RNA therapies for liver regeneration. What is the issue to solve? Ending liver disease as a …See details»
Ochre Bio Company Information - Funding, Investors, and More
The company Ochre Bio has raised a total of $39.75m in funding over 4 rounds. Key Insights: Series A: $30m; Seed: $9.6m; Unknown: $ Pre Seed: $150k; 2020. Ochre Bio Unknown …See details»
Podcast: Ochre Bio’s Approach To Precision Medicine In Liver …
1 day ago Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease. Related Content. …See details»